Provider Briefing: The Bupropion Supply Situation in 2026

Bupropion hydrochloride — marketed as Wellbutrin (SR, XL), Forfivo XL, and Zyban — remains one of the most widely prescribed antidepressants in the United States. Its unique norepinephrine-dopamine reuptake inhibitor (NDRI) mechanism, favorable weight and sexual side-effect profile, and versatility across multiple indications have made it a first-line or augmentation choice for millions of patients.

However, ongoing supply disruptions for certain Bupropion formulations are creating prescribing challenges. This briefing provides an overview of the current shortage, its implications for clinical practice, and practical tools to help your patients maintain access.

Shortage Timeline

Bupropion XL (24-hour extended-release tablets) first appeared on the ASHP Drug Shortage Database in 2023, with intermittent listings since. Key developments:

• 2023: Initial reports of spot shortages for Bupropion XL 300 mg from select generic manufacturers. FDA acknowledged supply disruptions tied to manufacturing issues.
• 2024: Shortage expanded. Par Pharmaceuticals, one of the largest generic Bupropion XL producers, reported supply limitations for the 300 mg and 150 mg strengths. Other manufacturers (Teva, Lupin, Cipla, Slate Run) reported varying availability.
• 2025: Supply improved for some strengths but remained inconsistent for XL 300 mg. ASHP maintained Bupropion XL on its Current Shortage list. The 450 mg (Forfivo XL) also experienced periodic unavailability.
• Early 2026: Situation stabilizing but not fully resolved. XL 300 mg remains the most constrained strength. SR and IR formulations are generally available.

Prescribing Implications

The shortage has several direct implications for prescribers:

Formulation Awareness

Understanding which formulations are available — and how they differ — is critical for navigating the shortage:

• Bupropion XL (extended-release, 24-hour): Once-daily dosing, most commonly prescribed. 150 mg and 300 mg strengths. The 300 mg is most affected by the shortage.
• Bupropion SR (sustained-release, 12-hour): Twice-daily dosing. 100 mg, 150 mg, and 200 mg strengths. Generally more available.
• Bupropion IR (immediate-release): Two to three times daily dosing. 75 mg and 100 mg strengths. Widely available but less convenient for patients.
• Aplenzin (Bupropion hydrobromide): Extended-release, once-daily. 174 mg, 348 mg, 522 mg. Different salt form with a separate supply chain. May be available when hydrochloride formulations are not.
• Forfivo XL: 450 mg once-daily. For patients already stabilized on 450 mg. Limited availability.

Dose Flexibility

When XL 300 mg is unavailable, consider:

• Prescribing two XL 150 mg tablets (taken together, once daily) — pharmacologically equivalent
• Converting to SR formulation: Bupropion XL 300 mg ≈ Bupropion SR 150 mg twice daily
• Switching to Aplenzin: Bupropion XL 300 mg ≈ Aplenzin 348 mg once daily

Document the clinical rationale for any formulation change and counsel patients on new dosing schedules.

Patient Communication

Patients may present with anxiety about running out of their antidepressant. Consider:

• Proactively discussing the shortage at appointments
• Providing backup prescriptions for alternative formulations
• Directing patients to Medfinder to check real-time pharmacy availability
• Advising patients to refill early (2-3 days before running out) and to check multiple pharmacies

Current Availability Picture

Based on ASHP data and pharmacy network reports:

• Bupropion XL 300 mg: Intermittent supply. Multiple manufacturers reporting limited availability. Expect continued inconsistency through mid-2026.
• Bupropion XL 150 mg: Generally available with occasional spot shortages.
• Bupropion SR (all strengths): Available at most pharmacies nationwide.
• Bupropion IR (all strengths): Widely available.
• Aplenzin 348 mg: Available but less commonly stocked — may require pharmacy to order.
• Forfivo XL 450 mg: Sporadic. Single-source product with limited distribution.

Availability varies significantly by region and pharmacy. Chain pharmacies (CVS, Walgreens, Walmart) and independent pharmacies may have different stock levels even in the same area due to distributor allocation differences.

Cost and Access Considerations

Cost can compound access challenges, particularly for uninsured or underinsured patients:

• Generic Bupropion XL (300 mg, 30 tablets): $15-$40 with discount coupons; retail without coupons ~$30-$70
• Generic Bupropion SR (150 mg, 60 tablets): $10-$25 with coupons
• Brand-name Wellbutrin XL: ~$2,700/month without insurance
• Aplenzin: ~$1,500-$2,000/month brand; no generic available

Patient assistance resources:

• Wellbutrin XL Savings Card: Eligible commercially insured patients may pay as little as $0. Available at wellbutrinxl.com.
• GSK Patient Assistance Program: Free medication for qualifying uninsured patients.
• Prescription Hope: Bupropion for $70/month for qualifying patients.
• Discount cards: GoodRx, SingleCare, and RxSaver can significantly reduce out-of-pocket costs for generic Bupropion.

Direct patients to our savings guide for Wellbutrin and the provider-focused provider guide to helping patients save.

Tools and Resources for Providers

• Medfinder for Providers: Real-time pharmacy availability search. Direct patients here or use it during appointments to identify pharmacies with stock.
• ASHP Drug Shortage Database: Official shortage tracking with manufacturer-level detail. Updated regularly.
• FDA Drug Shortages Page: Federal oversight and manufacturer communications.

Therapeutic Alternatives

If Bupropion is unavailable for an extended period and a formulation switch isn't feasible, consider these alternatives based on the patient's indication:

For depression (MDD):

• Venlafaxine (Effexor XR) — SNRI with norepinephrine activity; widely available generic
• Mirtazapine (Remeron) — Atypical antidepressant; useful for depression with insomnia/anorexia
• Vortioxetine (Trintellix) — Multimodal; cognitive benefits; brand-only, expensive
• Vilazodone (Viibryd) — SSRI + 5-HT1A partial agonist; generic available

For smoking cessation:

• Varenicline (Chantix) — Preferred per ATS guidelines; partial nicotinic agonist
• Nicotine replacement therapy — Patches, gum, lozenges (OTC)

For ADHD (off-label):

• Atomoxetine (Strattera) — Non-stimulant SNRI; FDA-approved for ADHD
• Guanfacine ER (Intuniv) — Alpha-2 agonist; FDA-approved for ADHD

See our patient-facing article on alternatives to Wellbutrin for information you can share with patients.

Looking Ahead

The Bupropion supply situation is expected to gradually improve through 2026 as additional generic manufacturing capacity comes online and existing manufacturers resolve production challenges. However, providers should plan for continued intermittent disruptions, particularly for XL 300 mg.

Key strategies:

• Maintain familiarity with SR and IR dosing conversions
• Consider Aplenzin as a supply-chain diversification strategy
• Proactively communicate with patients about backup plans
• Use Medfinder as part of your prescribing workflow

Final Thoughts

The Bupropion shortage is a logistics and manufacturing issue — not a clinical one. The drug remains highly effective and well-tolerated. By staying informed about availability, being flexible with formulations, and leveraging real-time tools, you can help your patients maintain uninterrupted access to this important medication.

For a step-by-step guide on helping patients navigate the shortage, see our companion article: How to Help Your Patients Find Wellbutrin in Stock.